2.93
+1.74%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Ardelyx
From its filings with the US Securities and Exchange Commission
Ardelyx is based in Fremont, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker ARDX. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $407.3m and a net loss of $61.6m. At that date it held total assets of $501.6m and shareholders' equity of $166.9m.
We are a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs. We currently market two therapies from the active ingredient tenapanor, a sodium/hydrogen exchanger (NHE3) inhibitor that was discovered and developed by Ardelyx. NHE3 is an antiporter expressed on the apical surface of the small and large intestines. Tenapanor is a minimally absorbed, first-in-class, oral, small molecule therapy.
Tenapanor, branded as IBSRELA®, is approved in the U.S. for the treatment of adults with irritable bowel syndrome with constipation. We believe that IBSRELA can bring meaningful benefit to the approximately 13 million Americans who suffer from the symptoms of IBS-C, many of whom continue to experience symptoms despite intervention with other therapies. We are seeking to further expand the IBSRELA eligible patient population to include patients with chronic idiopathic constipation (CIC), and have initiated a Phase 3 clinical trial evaluating tenapanor in adult CIC patients.
Tenapanor, branded as XPHOZAH®, is approved in the U.S. to reduce serum phosphorus in adults with chronic kidney disease on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
Quoted from its 10-K, filed 19 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 19 Jun 2014
- Employees
- 489
- Website
- ardelyx.com ↗
- Head office
- 34175 ARDENWOOD BLVD., FREMONT, CA, 94555
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Mr. David MottIndependent Chairman of the Board$309,997
- Mr. Michael RaabPresident, Chief Executive Officer, Director, since 2009$9.6m
- Ms. Sue HohenleitnerChief Financial Officer
- Mr. James BradyChief Human Resources Officer
- Ms. Elizabeth GrammerChief Legal and Administrative Officer$3.0m
- Dr. Edward ConnerChief Medical Officer
- Mr. Eric FosterChief Commercial Officer
- Mr. Mike KelliherChief Business Officer$3.0m
- Dr. Laura WilliamsInterim Chief Medical Officer$2.8m
- Mr. Robert BazemoreIndependent Director$257,497
- Mr. William BertrandIndependent Director$269,997
- Ms. Muna BhanjiIndependent Director$257,497
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 62
- Environment
- 42
- Social
- 99
- Governance
- 44
- Women in the workforce
- 62%
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Ardelyx Inc possesses a strong product portfolio, including innovative and proprietary drug candidates.
- The company has a highly skilled and experienced management team, which brings valuable expertise and insights to drive strategic decisions.
- Ardelyx Inc enjoys a good reputation and positive brand image in the pharmaceutical industry, enhancing its market credibility and investor confidence.
Weaknesses
- The company may face challenges related to the recent failure of some drug candidates in clinical trials, which could lead to setbacks in revenue generation and investor trust.
- Ardelyx Inc has a relatively limited pipeline, which increases its reliance on the success of a few key products.
- The company's current financial position may be a weakness as it lacks the resources to fully exploit market opportunities.
Opportunities
- The pharmaceutical industry is experiencing significant growth, creating opportunities for Ardelyx Inc to expand its market share and increase revenues.
- With ongoing research and development activities, the company has the potential to develop new and improved drug candidates, tapping into unaddressed medical needs.
- Strategic partnerships and collaborations with established pharmaceutical companies can provide Ardelyx Inc with access to additional resources and expertise.
Threats
- Competition within the pharmaceutical industry is intense, with existing players and new entrants vying for market dominance, posing a threat to Ardelyx Inc's market share.
- Regulatory challenges and stringent approval processes can hinder the company's ability to bring new drugs to market in a timely manner.
- Economic downturns or financial crises can impact overall healthcare spending, potentially affecting the demand for Ardelyx Inc's products.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.